ACADIA Pharmaceuticals

Youtube Subscribe

Open: 23.17 Close: 22.57 Change: -0.6

You're losing the opportunity of using an AI to get informed about ACADIA Pharmaceuticals Company Inc.

Are looking for the most relevant information about ACADIA Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in ACADIA Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ACADIA Pharmaceuticals are: Pharmaceuticals, Acadia, stock, CEO, Stephen, Davis, sell, and the most common words in the summary are: pharmaceutical, inc, acadia, job, san, stock, ago, . One of the sentences in the summary was: CEO Stephen Davis sold 51,563 shares of ACADIA Pharmaceuticals stock in …

Concept Map

Semantic Network

Stock Summary

ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders and rare diseases. It offers NUPLAZID (pimavanserin).

Today's Summary

CEO Stephen Davis sold 51,563 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Friday, October 6th. Acadia Pharmaceuticals stock ACAD, -0.23% surged 18% in premarket trading after the company expanded drug rights to a treatment for a neurological disorder. Acadia Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) Acadia is advancing breakthroughs in neuroscience to elevate life.

Today's News

CEO Stephen Davis sold 51,563 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Friday, October 6th. Acadia Pharmaceuticals stock ACAD, -0.23% surged 18% in premarket trading after the company expanded drug rights to a treatment for a neurological disorder. Acadia Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) Acadia is advancing breakthroughs in neuroscience to elevate life.

Stock Profile

"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California."

Keywords

How much time have you spent trying to decide whether investing in ACADIA Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ACADIA Pharmaceuticals are: Pharmaceuticals, Acadia, stock, CEO, Stephen, Davis, sell, and the most common words in the summary are: pharmaceutical, inc, acadia, job, san, stock, ago, . One of the sentences in the summary was: CEO Stephen Davis sold 51,563 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Friday, October 6th. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #pharmaceutical #inc #acadia #job #san #stock #ago.

Read more →

Youtube Subscribe

---